[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Asia Pacific Bioproduction Market Forecast to 2030 - Regional Analysis - by Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), and End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others)

May 2024 | 117 pages | ID: A91179AFD8EBEN
The Insight Partners

US$ 3,550.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The Asia Pacific bioproduction market was valued at US$ 4,791.34 million in 2022 and is expected to reach US$ 14,612.30 million by 2030; it is estimated to register a CAGR of 15.0% from 2022 to 2030.

Patent Expiry of Blockbuster Biologics Boosts Asia Pacific Bioproduction Market

Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. Patents on originator biologicals are expected to expire in the coming years.

Estimated patent and exclusivity expiry dates for best-selling biologicals are given in the following table.

Biologicals Expiry Dates

Biologicals Expiry Dates

Avastin January 2022

Cyramza May 2023

Adcetris August 2023

Abthrax October 2024

Gazyva/Gazyvaro November 2024

Darzalex May 2026

Ocrevus April 2027

Emgality September 2028

Hemlibra February 2028

Llumetri March 2028

Imfinzi September 2028

Mylotarg April 2028

Imfinzi September 2028

Mylotarg April 2028

Sylvant July 2034

The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the bioproduction market during the forecast period.

Asia Pacific Bioproduction Market Overview

The Asia Pacific bioproduction market is segmented into China, Japan, India, South Korea, Australia, South Korea, and the Rest of Asia Pacific. The growth of the market in Asia Pacific is anticipated to grow at a faster pace owing to factors such as growing need for superior treatment solutions, increasing focus on research and development activities, and favorable regulatory scenarios. Additionally, increasing investments and developing healthcare infrastructure to boost research activities are estimated to drive the Asia Pacific bioproduction market during 2022-2030.

In China, the demand for healthcare is increasing rapidly. Factors such as growing geriatric population, rising incidence of chronic diseases, and increasing government initiatives in the healthcare sector are driving the cell therapy market in China. Improvements in basic and private medical insurance plans have also accelerated the growth of the medical sector in the country. The rising income levels have led to the demand for more sophisticated healthcare services. The rise in the geriatric population has led to an increase in the specialty medical community in the country. In China, the growing prevalence of cancer is likely to increase the adoption of cell therapy. According to the National Central Cancer Registry of China, 4.3 million new cancer cases were registered in China.

Asia Pacific Bioproduction Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Bioproduction Market Segmentation

The Asia Pacific bioproduction market is categorized into product, application, equipment, end user, and country.

Based on product, the Asia Pacific bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held the largest Asia Pacific bioproduction market share in 2022.

In terms of application, the Asia Pacific bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held the largest Asia Pacific bioproduction market share in 2022.

By equipment, the Asia Pacific bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held the largest Asia Pacific bioproduction market share in 2022.

In terms of end user, the Asia Pacific bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held the largest Asia Pacific bioproduction market share in 2022.

By country, the Asia Pacific bioproduction market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific bioproduction market share in 2022.

Lonza Group AG, bbi-biotech GmbH, Danaher Corp, Sartorius AG, FUJIFILM Irvine Scientific Inc, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc. are some of the leading companies operating in the Asia Pacific bioproduction market.
1. INTRODUCTION

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. EXECUTIVE SUMMARY

2.1 Key Insights

3. RESEARCH METHODOLOGY

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. ASIA PACIFIC BIOPRODUCTION MARKET - KEY INDUSTRY DYNAMICS

4.1 Market Drivers
  4.1.1 Rising Adoption of Regenerative Medicines
  4.1.2 Increasing Prevalence of Chronic Diseases
4.2 Market Restraints
  4.2.1 High Cost of Cell Therapy and Biosimilar Manufacturing
4.3 Market Opportunities
  4.3.1 Patent Expiry of Blockbuster Biologics
4.4 Future Trends
  4.4.1 Shift Toward Automated Cell Therapy Manufacturing
4.5 Impact Analysis

5. BIOPRODUCTION MARKET - ASIA PACIFIC MARKET ANALYSIS

5.1 Asia Pacific Bioproduction Market Revenue (US$ Mn), 2020 - 2030

6. ASIA PACIFIC BIOPRODUCTION MARKET - REVENUE AND FORECAST TO 2030 - BY PRODUCT

6.1 Overview
6.2 Asia Pacific Bioproduction Market Revenue Share, by Product 2022 & 2030 (%)
6.3 Biologics and Biosimilars
  6.3.1 Overview
  6.3.2 Biologics and Biosimilars: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Vaccines
  6.4.1 Overview
  6.4.2 Vaccines: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Cell and Gene Therapies
  6.5.1 Overview
  6.5.2 Cell and Gene Therapies: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Nucleic Acid Therapeutics
  6.6.1 Overview
  6.6.2 Nucleic Acid Therapeutics: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
6.7 Others
  6.7.1 Overview
  6.7.2 Others: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)

7. ASIA PACIFIC BIOPRODUCTION MARKET - REVENUE AND FORECAST TO 2030 - BY APPLICATION

7.1 Overview
7.2 Asia Pacific Bioproduction Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Cancer
  7.3.1 Overview
  7.3.2 Cancer: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Cardiovascular Diseases
  7.4.1 Overview
  7.4.2 Cardiovascular Diseases: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Rheumatoid Arthritis
  7.5.1 Overview
  7.5.2 Rheumatoid Arthritis: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Hematological Disorders
  7.6.1 Overview
  7.6.2 Hematological Disorders: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Diabetes
  7.7.1 Overview
  7.7.2 Diabetes: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
7.8 Others
  7.8.1 Overview
  7.8.2 Others: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)

8. ASIA PACIFIC BIOPRODUCTION MARKET - REVENUE AND FORECAST TO 2030 - BY EQUIPMENT

8.1 Overview
8.2 Asia Pacific Bioproduction Market Revenue Share, by Equipment 2022 & 2030 (%)
8.3 Consumables and Accessories
  8.3.1 Overview
  8.3.2 Consumables and Accessories: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Downstream Equipment
  8.4.1 Overview
  8.4.2 Downstream Equipment: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Bioreactors
  8.5.1 Overview
  8.5.2 Bioreactors: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
    8.5.2.1 Asia Pacific: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
8.6 Upstream Equipment
  8.6.1 Overview
  8.6.2 Upstream Equipment: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)

9. ASIA PACIFIC BIOPRODUCTION MARKET - REVENUE AND FORECAST TO 2030 - BY END USER

9.1 Overview
9.2 Asia Pacific Bioproduction Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Biopharmaceutical Companies
  9.3.1 Overview
  9.3.2 Biopharmaceutical Companies: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Contract Manufacturing Organizations
  9.4.1 Overview
  9.4.2 Contract Manufacturing Organizations: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Others
  9.5.1 Overview
  9.5.2 Others: Asia Pacific Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)

10. ASIA PACIFIC BIOPRODUCTION MARKET - REVENUE AND FORECAST TO 2030 - COUNTRY ANALYSIS

10.1 Asia Pacific: Bioproduction Market
  10.1.1 Asia Pacific: Bioproduction Market, by Country, 2022 & 2030 (%)
    10.1.1.1 China: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
      10.1.1.1.1 China: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
      10.1.1.1.2 China: Bioproduction Market, by Product, 2020-2030 (US$ Million)
      10.1.1.1.3 China: Bioproduction Market, by Application, 2020-2030 (US$ Million)
      10.1.1.1.4 China: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
        10.1.1.1.4.1 China: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
      10.1.1.1.5 China: Bioproduction Market, by End User, 2020-2030 (US$ Million)
    10.1.1.2 India: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
      10.1.1.2.1 Overview
      10.1.1.2.2 India: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
      10.1.1.2.3 India: Bioproduction Market, by Product, 2020-2030 (US$ Million)
      10.1.1.2.4 India: Bioproduction Market, by Application, 2020-2030 (US$ Million)
      10.1.1.2.5 India: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
        10.1.1.2.5.1 India: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
      10.1.1.2.6 India: Bioproduction Market, by End User, 2020-2030 (US$ Million)
    10.1.1.3 Japan: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
      10.1.1.3.1 Overview
      10.1.1.3.2 Japan: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
      10.1.1.3.3 Japan: Bioproduction Market, by Product, 2020-2030 (US$ Million)
      10.1.1.3.4 Japan: Bioproduction Market, by Application, 2020-2030 (US$ Million)
      10.1.1.3.5 Japan: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
        10.1.1.3.5.1 Japan: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
      10.1.1.3.6 Japan: Bioproduction Market, by End User, 2020-2030 (US$ Million)
    10.1.1.4 Australia: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
      10.1.1.4.1 Overview
      10.1.1.4.2 Australia: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
      10.1.1.4.3 Australia: Bioproduction Market, by Product, 2020-2030 (US$ Million)
      10.1.1.4.4 Australia: Bioproduction Market, by Application, 2020-2030 (US$ Million)
      10.1.1.4.5 Australia: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
        10.1.1.4.5.1 Australia: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
      10.1.1.4.6 Australia: Bioproduction Market, by End User, 2020-2030 (US$ Million)
    10.1.1.5 South Korea: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
      10.1.1.5.1 Overview
      10.1.1.5.2 South Korea: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
      10.1.1.5.3 South Korea: Bioproduction Market, by Product, 2020-2030 (US$ Million)
      10.1.1.5.4 South Korea: Bioproduction Market, by Application, 2020-2030 (US$ Million)
      10.1.1.5.5 South Korea: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
        10.1.1.5.5.1 South Korea: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
      10.1.1.5.6 South Korea: Bioproduction Market, by End User, 2020-2030 (US$ Million)
    10.1.1.6 Rest of Asia Pacific: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
      10.1.1.6.1 Overview
      10.1.1.6.2 Rest of Asia Pacific: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
      10.1.1.6.3 Rest of Asia Pacific: Bioproduction Market, by Product, 2020-2030 (US$ Million)
      10.1.1.6.4 Rest of Asia Pacific: Bioproduction Market, by Application, 2020-2030 (US$ Million)
      10.1.1.6.5 Rest of Asia Pacific: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
        10.1.1.6.5.1 Rest of Asia Pacific: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
      10.1.1.6.6 Rest of Asia Pacific: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)

11. BIOPRODUCTION MARKET-INDUSTRY LANDSCAPE

11.1 Overview
11.2 Growth Strategies in the Bioproduction Market
11.3 Inorganic Growth Strategies
  11.3.1 Overview
11.4 Organic Growth Strategies
  11.4.1 Overview

12. COMPANY PROFILES

12.1 . Lonza Group AG
  12.1.1 Key Facts
  12.1.2 Business Description
  12.1.3 Products and Services
  12.1.4 Financial Overview
  12.1.5 SWOT Analysis
  12.1.6 Key Developments
12.2 bbi-biotech GmbH
  12.2.1 Key Facts
  12.2.2 Business Description
  12.2.3 Products and Services
  12.2.4 Financial Overview
  12.2.5 SWOT Analysis
  12.2.6 Key Developments
12.3 Danaher Corp
  12.3.1 Key Facts
  12.3.2 Business Description
  12.3.3 Products and Services
  12.3.4 Financial Overview
  12.3.5 SWOT Analysis
  12.3.6 Key Developments
12.4 Sartorius AG
  12.4.1 Key Facts
  12.4.2 Business Description
  12.4.3 Products and Services
  12.4.4 Financial Overview
  12.4.5 SWOT Analysis
  12.4.6 Key Developments
12.5 FUJIFILM Irvine Scientific Inc
  12.5.1 Key Facts
  12.5.2 Business Description
  12.5.3 Products and Services
  12.5.4 Financial Overview
  12.5.5 SWOT Analysis
  12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc
  12.6.1 Key Facts
  12.6.2 Business Description
  12.6.3 Products and Services
  12.6.4 Financial Overview
  12.6.5 SWOT Analysis
  12.6.6 Key Developments
12.7 Merck KGaA
  12.7.1 Key Facts
  12.7.2 Business Description
  12.7.3 Products and Services
  12.7.4 Financial Overview
  12.7.5 SWOT Analysis
  12.7.6 Key Developments
12.8 F. Hoffmann-La Roche Ltd
  12.8.1 Key Facts
  12.8.2 Business Description
  12.8.3 Products and Services
  12.8.4 Financial Overview
  12.8.5 SWOT Analysis
  12.8.6 Key Developments
12.9 Bio-Rad Laboratories Inc
  12.9.1 Key Facts
  12.9.2 Business Description
  12.9.3 Products and Services
  12.9.4 Financial Overview
  12.9.5 SWOT Analysis
  12.9.6 Key Developments

13. APPENDIX

13.1 About Us
13.2 Glossary of Terms


More Publications